Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women

Nicole U Stoffel, Christophe Zeder, Gary M Brittenham, Diego Moretti, Michael B Zimmermann, Nicole U Stoffel, Christophe Zeder, Gary M Brittenham, Diego Moretti, Michael B Zimmermann

Abstract

In iron-depleted women without anemia, oral iron supplements induce an increase in serum hepcidin (SHep) that persists for 24 hours, decreasing iron absorption from supplements given later on the same or next day. Consequently, iron absorption from supplements is highest if iron is given on alternate days. Whether this dosing schedule is also beneficial in women with iron-deficiency anemia (IDA) given high-dose iron supplements is uncertain. The primary objective of this study was to assess whether, in women with IDA, alternate-day administration of 100 and 200 mg iron increases iron absorption compared to consecutive-day iron administration. Secondary objectives were to correlate iron absorption with SHep and iron status parameters. We performed a cross-over iron absorption study in women with IDA (n=19; median hemoglobin 11.5 mg/dL; mean serum ferritin 10 mg/L) who received either 100 or 200 mg iron as ferrous sulfate given at 8 AM on days 2, 3 and 5 labeled with stable iron isotopes 57Fe, 58Fe and 54Fe; after a 16-day incorporation period, the other labeled dose was given at 8 AM on days 23, 24 and 26 (days 2, 3 and 5 of the second period). Iron absorption on days 2 and 3 (consecutive) and day 5 (alternate) was assessed by measuring erythrocyte isotope incorporation. For both doses, SHep was higher on day 3 than on day 2 (P<0.001) or day 5 (P<0.01) with no significant difference between days 2 and 5. Similarly, for both doses, fractional iron absorption (FIA) on days 2 and 5 was 40-50% higher than on day 3 (P<0.001), while absorption on day 2 did not differ significantly from day 5. There was no significant difference in the incidence of gastrointestinal side effects comparing the two iron doses (P=0.105). Alternate day dosing of oral iron supplements in anemic women may be preferable because it sharply increases FIA. If needed, to provide the same total amount of iron with alternate day dosing, twice the daily target dose should be given on alternate days, as total iron absorption from a single dose of 200 mg given on alternate days was approximately twice that from 100 mg given on consecutive days (P<0.001). In IDA, even if hepatic hepcidin expression is strongly suppressed by iron deficiency and erythropoietic drive, the intake of oral iron supplements leads to an acute hepcidin increase for 24 hours. The study was funded by ETH Zürich, Switzerland. This study has been registered at www.clinicaltrials.gov as #NCT03623997.

Copyright© 2020 Ferrata Storti Foundation.

Figures

Figure 1
Figure 1
Study design. SHep: serum hepcidin; RBC: red blood cells.
Figure 2
Figure 2
Serum hepcidin in iron-deficient anemic women. In women with iron deficiency anemia (IDA) who received 100 mg and 200 mg oral iron supplements on consecutive (day 3) and alternate days (day 5), serum hepcidin increases at 24 hours (h) and returns to baseline by 48 h .
Figure 3
Figure 3
Iron absorption in iron-deficient anemic women. (A) Fractional iron absorption from 100 and 200 mg oral iron doses was higher during alternate day dosing (day 5) compared to consecutive day dosing (day 3); (B) Total iron absorption from 100 and 200 mg oral iron doses was higher during alternate day dosing (day 5) compared to consecutive day dosing (day 3).
Figure 4
Figure 4
Serum hepcidin and transferrin saturation profiles in iron-deficient anemic women. (A) Serum hepcidin (Shep) profile during alternate day dosing (day 5) and consecutive day dosing (day 3) with 100 and 200 mg oral iron; (B) Transferrin saturation profile (TSAT) during alternate day dosing (day 5) and consecutive day dosing (day 3) with 100 and 200 mg oral iron.

References

    1. Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014; 123(5):615–624.
    1. Cogswell ME, Looker AC, Pfeiffer CM, et al. Assessment of iron deficiency in US preschool children and nonpregnant females of childbearing age: National Health and Nutrition Examination Survey 2003-2006. Am J Clin Nutr. 2009;89(5):1334–1342.
    1. Cook JD. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin Haematol. 2005;18(2):319–332.
    1. Camaschella C. Iron deficiency: new insights into diagnosis and treatment. Hematology Am Soc Hematol Educ Program. 2015;2015:8–13.
    1. CDC. Recommendations to Prevent and Control Iron Deficiency in the United States. Atlanta: Centers for Disease Control and Prevention (CDC) 1998. [cited 2018 21.09]; Available from:
    1. Stoltzfus RJ, Dreyfuss ML. Guidelines for the use of iron supplements to prevent and treat iron deficiency anemia: International Nutritional Anemia Consultative Group (INACG), 1998. Available from:
    1. Pavord S, Myers B, Robinson S, et al. UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol. 2012; 156(5):588–600.
    1. Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015;22;126(17):1981–1989.
    1. Tolkien Z, Stecher L, Mander AP, Pereira DI, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PloS One. 2015;10(2): e0117383.
    1. Kortman GA, Raffatellu M, Swinkels DW, Tjalsma H. Nutritional iron turned inside out: intestinal stress from a gut microbial perspective. FEMS Microbiol Rev 2014; 38(6):1202–1234
    1. Lund EK, Fairweather-Tait SJ, Wharf SG, Johnson IT. Chronic exposure to high levels of dietary iron fortification increases lipid peroxidation in the mucosa of the rat large intestine. J Nutr. 2001;131(11):2928–2931.
    1. Lund EK, Wharf SG, Fairweather-Tait SJ, Johnson IT. Oral ferrous sulfate supplements increase the free radical-generating capacity of feces from healthy volunteers. Am J Clin Nutr. 1999;69(2):250–255.
    1. Rimon E, Kagansky N, Kagansky M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005;118(10):1142–1147.
    1. Jaeggi T, Kortman GA, Moretti D, et al. Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut. 2015;64(5):731–742.
    1. Paganini D, Uyoga MA, Kortman GAM, et al. Prebiotic galacto-oligosaccharides mitigate the adverse effects of iron fortification on the gut microbiome: a randomised controlled study in Kenyan infants. Gut. 2017;66(11):1956–1967.
    1. Sangkhae V, Nemeth E. Regulation of the iron homeostatic hormone hepcidin. Adv Nutr. 2017;8(1):126–136.
    1. Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017;4(11): e524–e533.
    1. Schaap CC, Hendriks JC, Kortman GA, et al. Diurnal rhythm rather than dietary iron mediates daily hepcidin variations. Clin Chem. 2013;59(3):527–535.
    1. Troutt JS, Rudling M, Persson L, et al. Circulating human hepcidin-25 concentrations display a diurnal rhythm, increase with prolonged fasting, and are reduced by growth hormone administration. Clin Chem. 2012;58(8):1225–1232.
    1. Camaschella C. New insights into iron deficiency and iron deficiency anemia. Blood Rev. 2017;31(4):225–233.
    1. Pena-Rosas JP, De-Regil LM, Gomez Malave H, Flores-Urrutia MC, Dowswell T. Intermittent oral iron supplementation during pregnancy. Cochrane DB Syst Rev. 2015. 19(10):CD009997.
    1. Pena-Rosas JP, Nesheim MC, Garcia-Casal MN, et al. Intermittent iron supplementation regimens are able to maintain safe maternal hemoglobin concentrations during pregnancy in Venezuela. J Nutr. 2004; 134(5):1099–1104.
    1. Hotz K, Krayenbuehl PA, Walczyk T. Mobilization of storage iron is reflected in the iron isotopic composition of blood in humans. J Biol Inorg Chem. 2012;17(2):301–309.
    1. Brown E, Bradley B, Wennesland R, Hodges JL, Hopper J, Yamauchi H. Red Cell, Plasma, and Blood Volume in Healthy Women Measured by Radichromium Cell-Labeling and Hematocrit. J Clin Invest. 1962;41:2182–2190.
    1. Hosain F, Marsaglia G, Noyes W, Finch CA. The nature of internal iron exchange in man. Trans Assoc Am Physicians. 1962; 75:59–63.
    1. Hallberg L. Combating iron deficiency: daily administration of iron is far superior to weekly administration. Am J Clin Nutr. 1998;68(2):213–217.
    1. Zoller H, Koch RO, Theurl I, et al. Expression of the duodenal iron transporters divalent-metal transporter 1 and ferroportin 1 in iron deficiency and iron overload. Gastroenterology. 2001;120(6): 1412–1419.
    1. Stoffel NU, Zeder C, Fort E, Swinkels DW, Zimmermann MB, Moretti D. Prediction of human iron bioavailability using rapid c-ELISAs for human plasma hepcidin. Clin Chem Lab Med. 2017;26;55(8):1186–1192.
    1. Maeda H, Hitomi Y, Hirata R, et al. The effect of phlebotomy on serum erythropoietin levels in normal healthy subjects. Int J Hematol. 1992;55(2):111–115.
    1. Schotten N, Laarakkers CM, Roelofs RW, Origa R, van Kraaij MG, Swinkels DW. EPO and hepcidin plasma concentrations in blood donors and beta-thalassemia intermedia are not related to commercially tested plasma ERFE concentrations. Am J Hematol. 2017;92(3):E29–E31.

Source: PubMed

3
구독하다